Copy For Citation
Cilli A., Uzer F., Sevinç C., Coşkun F., Ursavaş A., Öner Ş., ...More
Pulmonary pharmacology & therapeutics, vol.71, pp.102099, 2021 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
71
-
Publication Date:
2021
-
Doi Number:
10.1016/j.pupt.2021.102099
-
Journal Name:
Pulmonary pharmacology & therapeutics
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
-
Page Numbers:
pp.102099
-
Keywords:
IPF, Nintedanib, Pirfenidone, Switch, ACUTE EXACERBATION, PIRFENIDONE, NINTEDANIB, SAFETY
-
Bursa Uludag University Affiliated:
Yes
Abstract
Background: The antifibrotic drugs nintedanib and pirfenidone reduce disease progression in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching first-line antifibrotic drug may required in IPF due to disease progression or intolerable adverse effects. The aim of this study was to assess the safety and efficacy of second-line antifibrotic treatment in patients with IPF.